Loading…
BRCA2 arg372hispolymorphism and epithelial ovarian cancer risk
The BRCA2 372 HH genotype defined by the BRCA2 N372H nonconservative amino acid substitution polymorphism was recently reported to be associated with a small increased risk of breast cancer. We investigated whether this polymorphism was associated with ovarian cancer risk by conducting British and A...
Saved in:
| Published in: | International journal of cancer 2003-01, Vol.103 (3), p.427-430 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 430 |
| container_issue | 3 |
| container_start_page | 427 |
| container_title | International journal of cancer |
| container_volume | 103 |
| creator | Auranen, Annika Spurdle, Amanda B. Chen, Xiaoqing Lipscombe, Julian Purdie, David M. Hopper, John L. Green, Adele Healey, Catherine S. Redman, Karen Dunning, Alison M. Pharoah, Paul D. Easton, Douglas F. Ponder, Bruce A.J. Chenevix‐Trench, Georgia Novik, Karen L. |
| description | The BRCA2 372 HH genotype defined by the BRCA2 N372H nonconservative amino acid substitution polymorphism was recently reported to be associated with a small increased risk of breast cancer. We investigated whether this polymorphism was associated with ovarian cancer risk by conducting British and Australian case‐control comparisons in parallel, including a total sample of 1,121 ovarian cancer cases and 2,643 controls. There was no difference in genotype frequency between control groups from the 2 studies (p = 0.9). The HH genotype was associated with an increased risk of ovarian cancer in both studies, and the risk estimate for the pooled studies was 1.36 (95% CI 1.04–1.77, p = 0.03). There was also a suggestion that this risk may be greater for ovarian cancers of the serous subtype for both studies, with an OR (95% CI) of 1.66 (1.17–2.54) for the 2 studies combined (p = 0.005). The BRCA2 372 HH genotype appears to be associated with an increased risk of ovarian cancer of a similar magnitude to that reported for breast cancer. © 2002 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/ijc.10814 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72879326</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72879326</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1294-a8e9a0f3bcb7febbf9768062d351ee9338779d669031a70b7c981464057d25ee3</originalsourceid><addsrcrecordid>eNpFkF1LwzAUhoMobk4v_APSK-_qTpI2aW6EWfxkIIheh7Q9dZnph8mm7N9bt4lX54X34cD7EHJO4YoCsKldlkPIaHJAxhSUjIHR9JCMhw5iSbkYkZMQlgCUppAckxFliaSCZWNyffOSz1hk_DuXbGFD37lN0_l-iE1k2irC3q4W6KxxUfdlvDVtVJq2RB95Gz5OyVFtXMCz_Z2Qt7vb1_whnj_fP-azedxTppLYZKgM1LwoC1ljUdRKigwEq3hKERXnmZSqEkIBp0ZCIUs1rBEJpLJiKSKfkMvd3953n2sMK93YUKJzpsVuHbRkmVSciQG82IProsFK9942xm_03-IBmO6Ab-tw89-D_lWpB5V6q1I_PuXbwH8A4KRkAw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72879326</pqid></control><display><type>article</type><title>BRCA2 arg372hispolymorphism and epithelial ovarian cancer risk</title><source>Wiley</source><creator>Auranen, Annika ; Spurdle, Amanda B. ; Chen, Xiaoqing ; Lipscombe, Julian ; Purdie, David M. ; Hopper, John L. ; Green, Adele ; Healey, Catherine S. ; Redman, Karen ; Dunning, Alison M. ; Pharoah, Paul D. ; Easton, Douglas F. ; Ponder, Bruce A.J. ; Chenevix‐Trench, Georgia ; Novik, Karen L.</creator><creatorcontrib>Auranen, Annika ; Spurdle, Amanda B. ; Chen, Xiaoqing ; Lipscombe, Julian ; Purdie, David M. ; Hopper, John L. ; Green, Adele ; Healey, Catherine S. ; Redman, Karen ; Dunning, Alison M. ; Pharoah, Paul D. ; Easton, Douglas F. ; Ponder, Bruce A.J. ; Chenevix‐Trench, Georgia ; Novik, Karen L.</creatorcontrib><description>The BRCA2 372 HH genotype defined by the BRCA2 N372H nonconservative amino acid substitution polymorphism was recently reported to be associated with a small increased risk of breast cancer. We investigated whether this polymorphism was associated with ovarian cancer risk by conducting British and Australian case‐control comparisons in parallel, including a total sample of 1,121 ovarian cancer cases and 2,643 controls. There was no difference in genotype frequency between control groups from the 2 studies (p = 0.9). The HH genotype was associated with an increased risk of ovarian cancer in both studies, and the risk estimate for the pooled studies was 1.36 (95% CI 1.04–1.77, p = 0.03). There was also a suggestion that this risk may be greater for ovarian cancers of the serous subtype for both studies, with an OR (95% CI) of 1.66 (1.17–2.54) for the 2 studies combined (p = 0.005). The BRCA2 372 HH genotype appears to be associated with an increased risk of ovarian cancer of a similar magnitude to that reported for breast cancer. © 2002 Wiley‐Liss, Inc.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.10814</identifier><identifier>PMID: 12471628</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adenocarcinoma, Clear Cell - genetics ; Adenocarcinoma, Mucinous - genetics ; Adult ; Aged ; Aged, 80 and over ; BRCA2 ; BRCA2 Protein - genetics ; Carcinoma, Endometrioid - genetics ; Case-Control Studies ; Cystadenocarcinoma, Serous - genetics ; DNA Mutational Analysis ; Female ; Genotype ; Humans ; Middle Aged ; Neoplasm Invasiveness - genetics ; Neoplasms, Glandular and Epithelial - genetics ; ovarian cancer ; Ovarian Neoplasms - genetics ; polymorphism ; Polymorphism, Genetic ; Risk Factors</subject><ispartof>International journal of cancer, 2003-01, Vol.103 (3), p.427-430</ispartof><rights>Copyright © 2002 Wiley‐Liss, Inc.</rights><rights>Copyright 2002 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.10814$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.10814$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12471628$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Auranen, Annika</creatorcontrib><creatorcontrib>Spurdle, Amanda B.</creatorcontrib><creatorcontrib>Chen, Xiaoqing</creatorcontrib><creatorcontrib>Lipscombe, Julian</creatorcontrib><creatorcontrib>Purdie, David M.</creatorcontrib><creatorcontrib>Hopper, John L.</creatorcontrib><creatorcontrib>Green, Adele</creatorcontrib><creatorcontrib>Healey, Catherine S.</creatorcontrib><creatorcontrib>Redman, Karen</creatorcontrib><creatorcontrib>Dunning, Alison M.</creatorcontrib><creatorcontrib>Pharoah, Paul D.</creatorcontrib><creatorcontrib>Easton, Douglas F.</creatorcontrib><creatorcontrib>Ponder, Bruce A.J.</creatorcontrib><creatorcontrib>Chenevix‐Trench, Georgia</creatorcontrib><creatorcontrib>Novik, Karen L.</creatorcontrib><title>BRCA2 arg372hispolymorphism and epithelial ovarian cancer risk</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>The BRCA2 372 HH genotype defined by the BRCA2 N372H nonconservative amino acid substitution polymorphism was recently reported to be associated with a small increased risk of breast cancer. We investigated whether this polymorphism was associated with ovarian cancer risk by conducting British and Australian case‐control comparisons in parallel, including a total sample of 1,121 ovarian cancer cases and 2,643 controls. There was no difference in genotype frequency between control groups from the 2 studies (p = 0.9). The HH genotype was associated with an increased risk of ovarian cancer in both studies, and the risk estimate for the pooled studies was 1.36 (95% CI 1.04–1.77, p = 0.03). There was also a suggestion that this risk may be greater for ovarian cancers of the serous subtype for both studies, with an OR (95% CI) of 1.66 (1.17–2.54) for the 2 studies combined (p = 0.005). The BRCA2 372 HH genotype appears to be associated with an increased risk of ovarian cancer of a similar magnitude to that reported for breast cancer. © 2002 Wiley‐Liss, Inc.</description><subject>Adenocarcinoma, Clear Cell - genetics</subject><subject>Adenocarcinoma, Mucinous - genetics</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>BRCA2</subject><subject>BRCA2 Protein - genetics</subject><subject>Carcinoma, Endometrioid - genetics</subject><subject>Case-Control Studies</subject><subject>Cystadenocarcinoma, Serous - genetics</subject><subject>DNA Mutational Analysis</subject><subject>Female</subject><subject>Genotype</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness - genetics</subject><subject>Neoplasms, Glandular and Epithelial - genetics</subject><subject>ovarian cancer</subject><subject>Ovarian Neoplasms - genetics</subject><subject>polymorphism</subject><subject>Polymorphism, Genetic</subject><subject>Risk Factors</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpFkF1LwzAUhoMobk4v_APSK-_qTpI2aW6EWfxkIIheh7Q9dZnph8mm7N9bt4lX54X34cD7EHJO4YoCsKldlkPIaHJAxhSUjIHR9JCMhw5iSbkYkZMQlgCUppAckxFliaSCZWNyffOSz1hk_DuXbGFD37lN0_l-iE1k2irC3q4W6KxxUfdlvDVtVJq2RB95Gz5OyVFtXMCz_Z2Qt7vb1_whnj_fP-azedxTppLYZKgM1LwoC1ljUdRKigwEq3hKERXnmZSqEkIBp0ZCIUs1rBEJpLJiKSKfkMvd3953n2sMK93YUKJzpsVuHbRkmVSciQG82IProsFK9942xm_03-IBmO6Ab-tw89-D_lWpB5V6q1I_PuXbwH8A4KRkAw</recordid><startdate>20030120</startdate><enddate>20030120</enddate><creator>Auranen, Annika</creator><creator>Spurdle, Amanda B.</creator><creator>Chen, Xiaoqing</creator><creator>Lipscombe, Julian</creator><creator>Purdie, David M.</creator><creator>Hopper, John L.</creator><creator>Green, Adele</creator><creator>Healey, Catherine S.</creator><creator>Redman, Karen</creator><creator>Dunning, Alison M.</creator><creator>Pharoah, Paul D.</creator><creator>Easton, Douglas F.</creator><creator>Ponder, Bruce A.J.</creator><creator>Chenevix‐Trench, Georgia</creator><creator>Novik, Karen L.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20030120</creationdate><title>BRCA2 arg372hispolymorphism and epithelial ovarian cancer risk</title><author>Auranen, Annika ; Spurdle, Amanda B. ; Chen, Xiaoqing ; Lipscombe, Julian ; Purdie, David M. ; Hopper, John L. ; Green, Adele ; Healey, Catherine S. ; Redman, Karen ; Dunning, Alison M. ; Pharoah, Paul D. ; Easton, Douglas F. ; Ponder, Bruce A.J. ; Chenevix‐Trench, Georgia ; Novik, Karen L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1294-a8e9a0f3bcb7febbf9768062d351ee9338779d669031a70b7c981464057d25ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adenocarcinoma, Clear Cell - genetics</topic><topic>Adenocarcinoma, Mucinous - genetics</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>BRCA2</topic><topic>BRCA2 Protein - genetics</topic><topic>Carcinoma, Endometrioid - genetics</topic><topic>Case-Control Studies</topic><topic>Cystadenocarcinoma, Serous - genetics</topic><topic>DNA Mutational Analysis</topic><topic>Female</topic><topic>Genotype</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness - genetics</topic><topic>Neoplasms, Glandular and Epithelial - genetics</topic><topic>ovarian cancer</topic><topic>Ovarian Neoplasms - genetics</topic><topic>polymorphism</topic><topic>Polymorphism, Genetic</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Auranen, Annika</creatorcontrib><creatorcontrib>Spurdle, Amanda B.</creatorcontrib><creatorcontrib>Chen, Xiaoqing</creatorcontrib><creatorcontrib>Lipscombe, Julian</creatorcontrib><creatorcontrib>Purdie, David M.</creatorcontrib><creatorcontrib>Hopper, John L.</creatorcontrib><creatorcontrib>Green, Adele</creatorcontrib><creatorcontrib>Healey, Catherine S.</creatorcontrib><creatorcontrib>Redman, Karen</creatorcontrib><creatorcontrib>Dunning, Alison M.</creatorcontrib><creatorcontrib>Pharoah, Paul D.</creatorcontrib><creatorcontrib>Easton, Douglas F.</creatorcontrib><creatorcontrib>Ponder, Bruce A.J.</creatorcontrib><creatorcontrib>Chenevix‐Trench, Georgia</creatorcontrib><creatorcontrib>Novik, Karen L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Auranen, Annika</au><au>Spurdle, Amanda B.</au><au>Chen, Xiaoqing</au><au>Lipscombe, Julian</au><au>Purdie, David M.</au><au>Hopper, John L.</au><au>Green, Adele</au><au>Healey, Catherine S.</au><au>Redman, Karen</au><au>Dunning, Alison M.</au><au>Pharoah, Paul D.</au><au>Easton, Douglas F.</au><au>Ponder, Bruce A.J.</au><au>Chenevix‐Trench, Georgia</au><au>Novik, Karen L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BRCA2 arg372hispolymorphism and epithelial ovarian cancer risk</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2003-01-20</date><risdate>2003</risdate><volume>103</volume><issue>3</issue><spage>427</spage><epage>430</epage><pages>427-430</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><notes>Dr. Novik's current affiliation is: The Wellcome Sanger Institute, Hinxton, Cambridge, UK.</notes><notes>The first two authors contributed equally to this work.</notes><notes>Fax: +617‐3362‐0105</notes><notes>Dr. Auranen's current affiliation is: Department of Obstetrics and Gynecology, Turku University Hospital, Turku, Finland.</notes><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>The BRCA2 372 HH genotype defined by the BRCA2 N372H nonconservative amino acid substitution polymorphism was recently reported to be associated with a small increased risk of breast cancer. We investigated whether this polymorphism was associated with ovarian cancer risk by conducting British and Australian case‐control comparisons in parallel, including a total sample of 1,121 ovarian cancer cases and 2,643 controls. There was no difference in genotype frequency between control groups from the 2 studies (p = 0.9). The HH genotype was associated with an increased risk of ovarian cancer in both studies, and the risk estimate for the pooled studies was 1.36 (95% CI 1.04–1.77, p = 0.03). There was also a suggestion that this risk may be greater for ovarian cancers of the serous subtype for both studies, with an OR (95% CI) of 1.66 (1.17–2.54) for the 2 studies combined (p = 0.005). The BRCA2 372 HH genotype appears to be associated with an increased risk of ovarian cancer of a similar magnitude to that reported for breast cancer. © 2002 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>12471628</pmid><doi>10.1002/ijc.10814</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7136 |
| ispartof | International journal of cancer, 2003-01, Vol.103 (3), p.427-430 |
| issn | 0020-7136 1097-0215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72879326 |
| source | Wiley |
| subjects | Adenocarcinoma, Clear Cell - genetics Adenocarcinoma, Mucinous - genetics Adult Aged Aged, 80 and over BRCA2 BRCA2 Protein - genetics Carcinoma, Endometrioid - genetics Case-Control Studies Cystadenocarcinoma, Serous - genetics DNA Mutational Analysis Female Genotype Humans Middle Aged Neoplasm Invasiveness - genetics Neoplasms, Glandular and Epithelial - genetics ovarian cancer Ovarian Neoplasms - genetics polymorphism Polymorphism, Genetic Risk Factors |
| title | BRCA2 arg372hispolymorphism and epithelial ovarian cancer risk |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T18%3A22%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BRCA2%20arg372hispolymorphism%20and%20epithelial%20ovarian%20cancer%20risk&rft.jtitle=International%20journal%20of%20cancer&rft.au=Auranen,%20Annika&rft.date=2003-01-20&rft.volume=103&rft.issue=3&rft.spage=427&rft.epage=430&rft.pages=427-430&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.10814&rft_dat=%3Cproquest_pubme%3E72879326%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p1294-a8e9a0f3bcb7febbf9768062d351ee9338779d669031a70b7c981464057d25ee3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72879326&rft_id=info:pmid/12471628&rfr_iscdi=true |